首頁
Global Biopharmaceutical Company - Br...

11月 2025Global Biopharmaceutical...的市場佔有率分析

Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

健康 > 生物技術和製藥

域名bmsfrance.fr

成立年份--

僱員501 - 1000

年度營收--

Global Biopharmaceutical Company - Br...

Global Biopharmaceutical Company - Br...（包含公司地區）

bmsfrance.fr

查看更多網站流量與參與度資訊

Global Biopharmaceutical Company - Br...的熱門網域總造訪量

了解Global Biopharmaceutical Company - Br...市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

Global Biopharmaceutical Company - Br...的熱門網域平均造訪時長

分析Global Biopharmaceutical Company - Br...參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

Global Biopharmaceutical Company - Br...的熱門網域平均頁面瀏覽量

了解Global Biopharmaceutical Company - Br...如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

Global Biopharmaceutical Company - Br...按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

boehringer-ingelheim.fr公司名Boehringer Ingelheim僱員> 10001總部德國, Ingelheim am Rhein年度營收> $1B訪問總量--健康 > 生物技術和製藥

使用的熱門技術Global Biopharmaceutical Company - Br...

这些是Global Biopharmaceutical Company - Br...顶级域名使用的行业网站技术

付費廣告 (7)

DoubleClick

轉換與分析 (5)

DoubleClick Floodlight

社群 (5)

Instagram

音訊視訊媒體 (2)

YouTube

更多技術

7

檢視所有

新聞與訊號來自Global Biopharmaceutical Company - Br...

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Bmsfrance acquired Myokardia for $13B on Oct 12th '20.Bristol-Myers Squibb said on Monday it would buy MyoKardia for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on cancer drugs.

新聞Bmsfrance acquired Celgene Corp. for $74B on Jan 1st '19.REUTERS/Regis Duvignau/File Photo New York-based Bristol-Myers bought Celgene for more than $74 billion in a deal announced last January.

新聞Domain Therapeutics SA partnered with Bmsfrance on Feb 27th '18.Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the research and development of new drug candidates that target transmembrane receptors, today announces the signing of a licensing agreement for its bioSens-All™ technology with Bristol-Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.